Boehringer takes Imdelltra rival straight to first line
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
